{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-065322","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.353921+00:00","generated_at":"2026-06-01T08:23:31.325090+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Apogee Therapeutics appoints Lisa Bollinger, MD to board of directors","bullets":["Lisa Bollinger, MD elected as Class II director, effective May 28, 2024.","Bollinger brings 30+ years in drug development; most recently VP Regulatory Affairs at Merck (MRK).","She also served as VP Global Patient Safety at Amgen and 12 years at FDA.","Will serve on the Nominating and Corporate Governance Committee.","Appointment adds regulatory and safety expertise as Apogee advances two clinical programs."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-065322","json":"https://secwatch.observer/filing/0001104659-24-065322.json","markdown":"https://secwatch.observer/filing/0001104659-24-065322.md","text":"https://secwatch.observer/filing/0001104659-24-065322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924065322/0001104659-24-065322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924065322/tm2415611d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:23:31.325090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bcf25cecb9","claim":"Lisa L. Bollinger was elected as Class II director at Apogee Therapeutics, Inc..","evidence_excerpt":"the board of directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) elected Lisa L. Bollinger, M.D. to serve as a Class II director of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1974640/000110465924065322/0001104659-24-065322-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Class II director"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}